UNCY · Company research
Unicycive Therapeutics, Inc. (UNCY): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
33records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| UNCY Shareholder Alert: Unicycive Therapeutics, Inc. - GlobeNewswire | UNCY Shareholder Alert: Unicycive Therapeutics, Inc. GlobeNewswire | View source ↗ | GlobeNewswire | Oct 19, 2026 | neutral | 0 | 0.6 |
| ROSEN, RECOGNIZED TRIAL ATTORNEYS, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL | Rosen Law Firm has filed securities class action lawsuits against Anavex Life Sciences Corp. (AVXL) for allegedly making false statements about internal controls and regulatory challenges related to former CEO misconduct. Similar lawsuits have been filed against AppLovin Corporation (APP) and Unicycive Therapeutics, Inc. (UNCY). Investors have until November 30, 2026 to become lead plaintiffs. | View source ↗ | GlobeNewswire Inc. | Oct 18, 2026 | bearish | -1 | 1 |
| UNICYCIVE DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY | Rosen Law Firm is notifying investors about securities class action lawsuits, including one against Unicycive Therapeutics for allegedly making false statements about its manufacturing vendor's FDA compliance and the regulatory approval timeline for its drug oxylanthanum carbonate. The lead plaintiff deadline is November 2, 2026. Similar lawsuits have been filed against Webull Corporation and Alphabet Inc. | View source ↗ | GlobeNewswire Inc. | Oct 18, 2026 | bearish | -1 | 1 |
| Anthropic Strikes Deal With California To Roll Out Claude Across State Agencies - Stocktwits | Anthropic Strikes Deal With California To Roll Out Claude Across State Agencies Stocktwits | View source ↗ | Stocktwits | Oct 17, 2026 | neutral | 0 | 0.6 |
| Unicycive Therapeutics, Inc. Class Action Reminder - Robbins LLP Encourages UNCY Investors to Contact the Firm About Their Rights | Robbins LLP reminds investors of a class action lawsuit against Unicycive Therapeutics (UNCY) for allegedly failing to disclose that it had not inspected its third-party manufacturing vendor's facility to ensure FDA deficiencies were resolved. The FDA issued a Complete Response Letter in June 2026 citing the same manufacturing deficiencies as a previous CRL, causing UNCY stock to drop 39.1% to $4.69 per share. The class period covers purchases between December 29, 2025 and June 29, 2026, with a lead plaintiff deadline of November 2, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bearish | -1 | 1 |
| Unicycive Therapeutics, Inc. Class Action Reminder - Robbins LLP Encourages UNCY Investors to Contact the Firm About Their Rights | Robbins LLP reminds investors of a class action lawsuit against Unicycive Therapeutics (UNCY) for allegedly failing to disclose that it had not inspected its third-party manufacturing vendor's facility to ensure FDA deficiencies were resolved. The FDA issued a Complete Response Letter in June 2026 citing the same manufacturing deficiencies as a previous CRL, causing UNCY stock to drop 39.1% to $4.69 per share. The class period covers purchases between December 29, 2025 and June 29, 2026, with a lead plaintiff deadline of November 2, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bearish | -1 | 1 |
| Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit | Unicycive Therapeutics (UNCY) shareholders are urged to file claims in a securities fraud class action lawsuit. The company's stock fell 39.1% on June 30, 2026, after the FDA issued a Complete Response Letter citing the same third-party manufacturing deficiencies as a previous rejection. The lawsuit alleges defendants made false statements and failed to disclose that the company had not properly audited its manufacturing vendor's compliance with FDA standards. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bearish | -1 | 1 |
| Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit | Unicycive Therapeutics (UNCY) shareholders are urged to file claims in a securities fraud class action lawsuit. The company's stock fell 39.1% on June 30, 2026, after the FDA issued a Complete Response Letter citing the same third-party manufacturing deficiencies as a previous rejection. The lawsuit alleges defendants made false statements and failed to disclose that the company had not properly audited its manufacturing vendor's compliance with FDA standards. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bearish | -1 | 1 |
| UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time? - Stocktwits | UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time? Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval - Stocktwits | UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| Markets & Stocks - FinancialContent | Markets & Stocks FinancialContent | View source ↗ | FinancialContent | Oct 13, 2026 | neutral | 0 | 0.6 |
| UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt - FinancialContent | UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt FinancialContent | View source ↗ | FinancialContent | Oct 13, 2026 | neutral | 0 | 0.6 |
| Should I buy Unicycive Therapeutics (UNCY) - Zacks Investment Research | Should I buy Unicycive Therapeutics (UNCY) Zacks Investment Research | View source ↗ | Zacks Investment Research | Oct 13, 2026 | neutral | 0 | 0.6 |
| Unicycive Therapeutics (UNCY) Short Interest & Short Float | Updated Oct 2026 - MarketBeat | Unicycive Therapeutics (UNCY) Short Interest & Short Float | Updated Oct 2026 MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| UNCY UPCOMING DEADLINE: Levi & Korsinsky Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm - PR Newswire | UNCY UPCOMING DEADLINE: Levi & Korsinsky Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm PR Newswire | View source ↗ | PR Newswire | Oct 7, 2026 | neutral | 0 | 0.6 |
| Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics, Inc. (UNCY), Hims & Hers Health, Inc. (HIMS), and Beta Bionics, Inc. (BBNX) Announced by Holzer & Holzer, LLC | Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Unicycive Therapeutics, Hims & Hers Health, and Beta Bionics. The lawsuits allege materially false statements and non-disclosure of material facts regarding regulatory risks, deceptive billing practices, data sharing, and device safety issues. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by November 2-3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics, Inc. (UNCY), Hims & Hers Health, Inc. (HIMS), and Beta Bionics, Inc. (BBNX) Announced by Holzer & Holzer, LLC | Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Unicycive Therapeutics, Hims & Hers Health, and Beta Bionics. The lawsuits allege materially false statements and non-disclosure of material facts regarding regulatory risks, deceptive billing practices, data sharing, and device safety issues. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by November 2-3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY | A securities class action lawsuit has been filed against Unicycive Therapeutics, Inc. (UNCY) for allegedly making materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims the company failed to disclose that it had not inspected the vendor's facility or audited its compliance with manufacturing practices, creating undisclosed risks of regulatory delays for its oxylanthanum carbonate drug. Investors who purchased UNCY securities between December 29, 2025 and June 29, 2026 may be eligible for compensation. The lead plaintiff deadline is November 2, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY | A securities class action lawsuit has been filed against Unicycive Therapeutics, Inc. (UNCY) for allegedly making materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims the company failed to disclose that it had not inspected the vendor's facility or audited its compliance with manufacturing practices, creating undisclosed risks of regulatory delays for its oxylanthanum carbonate drug. Investors who purchased UNCY securities between December 29, 2025 and June 29, 2026 may be eligible for compensation. The lead plaintiff deadline is November 2, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit | Unicycive Therapeutics faces a securities fraud class action lawsuit after the FDA issued a Complete Response Letter (CRL) on June 30, 2026, citing the same third-party manufacturing deficiencies as a previous rejection. The stock fell 39.1% on the news. The lawsuit alleges the company failed to disclose that it had not inspected its manufacturing vendor's facility or audited compliance with manufacturing practices, and lacked reasonable basis to believe deficiencies were resolved. The deadline to file a lead plaintiff motion is November 2, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bearish | -1 | 1 |
| Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Unicycive Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims Unicycive failed to properly audit the vendor's facility and lacked reasonable basis for positive statements about regulatory approval prospects for oxylanthanum carbonate. Investors who purchased securities between December 29, 2025 and June 29, 2026 may be eligible to join the case. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bearish | -1 | 1 |
| DEADLINE ALERT for HYLN, HIMS, UNCY, BIDU: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions | Law Offices of Howard G. Smith has filed securities fraud class action lawsuits against four publicly-traded companies: Hyliion Holdings Corp., Hims & Hers Health Inc., Unicycive Therapeutics Inc., and Baidu Inc. The lawsuits allege that defendants made materially false and misleading statements and failed to disclose material adverse facts about their respective businesses. Investors have until specified deadlines in late October and November 2026 to file lead plaintiff motions. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bearish | -1 | 1 |
| DEADLINE ALERT for HYLN, HIMS, UNCY, BIDU: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions | Law Offices of Howard G. Smith has filed securities fraud class action lawsuits against four publicly-traded companies: Hyliion Holdings Corp., Hims & Hers Health Inc., Unicycive Therapeutics Inc., and Baidu Inc. The lawsuits allege that defendants made materially false and misleading statements and failed to disclose material adverse facts about their respective businesses. Investors have until specified deadlines in late October and November 2026 to file lead plaintiff motions. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bearish | -1 | 1 |
| Unicycive Therapeutics (NasdaqCM:UNCY) Stock Forecast & Analyst Predictions - Simply Wall Street | Unicycive Therapeutics (NasdaqCM:UNCY) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 30, 2026 | neutral | 0 | 0.6 |
| UNCY Should I Buy - Intellectia AI | UNCY Should I Buy Intellectia AI | View source ↗ | Intellectia AI | Sep 26, 2026 | neutral | 0 | 0.6 |
| UNCY Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire | UNCY Stockholders Have Rights – If You Lost Money Investing GlobeNewswire | View source ↗ | GlobeNewswire | Sep 25, 2026 | neutral | 0 | 0.6 |
| UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact SueWallSt - Morningstar | UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact SueWallSt Morningstar | View source ↗ | Morningstar | Sep 24, 2026 | neutral | 0 | 0.6 |
| UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky - PR Newswire | UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | Sep 23, 2026 | neutral | 0 | 0.6 |
| Understanding Momentum Shifts in (UNCY) - Stock Traders Daily | Understanding Momentum Shifts in (UNCY) Stock Traders Daily | View source ↗ | Stock Traders Daily | Aug 28, 2026 | neutral | 0 | 0.6 |
| Unicycive Reports $61.4M in Cash and Securities as FDA Assigns Inspection - Stock Titan | Unicycive Reports $61.4M in Cash and Securities as FDA Assigns Inspection Stock Titan | View source ↗ | Stock Titan | Aug 12, 2026 | neutral | 0 | 0.6 |
| Unicycive’s kidney drug hits FDA setback as label talks continue - Stock Titan | Unicycive’s kidney drug hits FDA setback as label talks continue Stock Titan | View source ↗ | Stock Titan | Jun 30, 2026 | neutral | 0 | 0.6 |
| UNCY Stock On Track For Worst Day In About A Year Ahead Of FDA Decision On Lead Drug - Yahoo Finance | UNCY Stock On Track For Worst Day In About A Year Ahead Of FDA Decision On Lead Drug Yahoo Finance | View source ↗ | Yahoo Finance | Jun 26, 2026 | neutral | 0 | 0.6 |
| Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing? - Yahoo Finance | Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing? Yahoo Finance | View source ↗ | Yahoo Finance | May 14, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.